menu
    • menu
    [{"orgOrder":0,"company":"Iltoo Pharma","sponsor":"Iltoo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Endocrinology","graph2":"Phase II","graph3":"Iltoo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iltoo Pharma \/ Iltoo Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Iltoo Pharma \/ Iltoo Pharma"},{"orgOrder":0,"company":"Iltoo Pharma","sponsor":"Iltoo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"ILT-101","moa":"Interleukin-2 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Iltoo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iltoo Pharma \/ Iltoo Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Iltoo Pharma \/ Iltoo Pharma"},{"orgOrder":0,"company":"Iltoo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"ILT-101","moa":"Interleukin-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Iltoo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iltoo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Iltoo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Iltoo Pharma","sponsor":"Iltoo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"Interleukin-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Iltoo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iltoo Pharma \/ Iltoo Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Iltoo Pharma \/ Iltoo Pharma"},{"orgOrder":0,"company":"Iltoo Pharma","sponsor":"Iltoo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Interleukin-2","moa":"Interleukin-2 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Iltoo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iltoo Pharma \/ Iltoo Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Iltoo Pharma \/ Iltoo Pharma"},{"orgOrder":0,"company":"Iltoo Pharma","sponsor":"Iltoo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ILT101","moa":"Interleukin-2 receptor subunit beta; Interleukin-2 receptor subunit alpha; Cytokine receptor common subunit gamma","graph1":"Undisclosed","graph2":"Phase I","graph3":"Iltoo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iltoo Pharma \/ Iltoo Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Iltoo Pharma \/ Iltoo Pharma"},{"orgOrder":0,"company":"Iltoo Pharma","sponsor":"Iltoo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ILT101","moa":"Interleukin-2 receptor subunit beta; Interleukin-2 receptor subunit alpha; Cytokine receptor common subunit gamma","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Iltoo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iltoo Pharma \/ Iltoo Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Iltoo Pharma \/ Iltoo Pharma"},{"orgOrder":0,"company":"Iltoo Pharma","sponsor":"Iltoo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ILT101","moa":"Interleukin-2 receptor subunit beta; Interleukin-2 receptor subunit alpha; Cytokine receptor common subunit gamma","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Iltoo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iltoo Pharma \/ Iltoo Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Iltoo Pharma \/ Iltoo Pharma"},{"orgOrder":0,"company":"Iltoo Pharma","sponsor":"Iltoo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Recombinant Human IL-2","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"Iltoo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iltoo Pharma \/ Iltoo Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Iltoo Pharma \/ Iltoo Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Iltoo Pharma

    Menu

    Iltoo Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Iltoo Pharma

                            France arrow
                            BOS Manchester
                            Not Confirmed

                            Iltoo Pharma

                            France arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Recipient : Assistance Publique – Hôpitaux de Paris

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes

                            Details : Cyclosporin is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            December 10, 2021

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Recipient : Assistance Publique – Hôpitaux de Paris

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Iltoo Pharma

                            France arrow
                            BOS Manchester
                            Not Confirmed

                            Iltoo Pharma

                            France arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ILT101

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Assistance Publique – Hôpitaux de Paris

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19

                            Details : ILT101 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 22, 2020

                            Lead Product(s) : ILT101

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Assistance Publique – Hôpitaux de Paris

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Iltoo Pharma

                            France arrow
                            BOS Manchester
                            Not Confirmed

                            Iltoo Pharma

                            France arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ILT101

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Recipient : Assistance Publique – Hôpitaux de Paris

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder

                            Details : ILT101 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Bipolar Disorder.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 21, 2019

                            Lead Product(s) : ILT101

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Recipient : Assistance Publique – Hôpitaux de Paris

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Iltoo Pharma

                            France arrow
                            BOS Manchester
                            Not Confirmed

                            Iltoo Pharma

                            France arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interleukin-2

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase I/ Phase II

                            Recipient : Assistance Publique – Hôpitaux de Paris

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Low-dose Interleukin-2 in Women With Unexplained Miscarriages

                            Details : Interleukin-2 is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Abortion, Habitual.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 03, 2019

                            Lead Product(s) : Interleukin-2

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Assistance Publique – Hôpitaux de Paris

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Iltoo Pharma

                            France arrow
                            BOS Manchester
                            Not Confirmed

                            Iltoo Pharma

                            France arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ILT101

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Assistance Publique – Hôpitaux de Paris

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers

                            Details : ILT101 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 11, 2019

                            Lead Product(s) : ILT101

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Assistance Publique – Hôpitaux de Paris

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Iltoo Pharma

                            France arrow
                            BOS Manchester
                            Not Confirmed

                            Iltoo Pharma

                            France arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ILT-101

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase II

                            Recipient : Assistance Publique – Hôpitaux de Paris

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Low-dose IL-2 in Birch Pollen Allergy

                            Details : ILT-101 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinoconjunctivitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 17, 2018

                            Lead Product(s) : ILT-101

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase II

                            Recipient : Assistance Publique – Hôpitaux de Paris

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Iltoo Pharma

                            France arrow
                            BOS Manchester
                            Not Confirmed

                            Iltoo Pharma

                            France arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ILT-101

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)

                            Details : ILT-101 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lupus Erythematosus, Systemic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 04, 2016

                            Lead Product(s) : ILT-101

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Iltoo Pharma

                            France arrow
                            BOS Manchester
                            Not Confirmed

                            Iltoo Pharma

                            France arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human IL-2

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Recipient : Assistance Publique – Hôpitaux de Paris

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes

                            Details : Recombinant Human IL-2 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 08, 2015

                            Lead Product(s) : Recombinant Human IL-2

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Recipient : Assistance Publique – Hôpitaux de Paris

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Iltoo Pharma

                            France arrow
                            BOS Manchester
                            Not Confirmed

                            Iltoo Pharma

                            France arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interleukin 2

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Recipient : Assistance Publique – Hôpitaux de Paris

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases

                            Details : Interleukin 2 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Arthritis, Rheumatoid.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 20, 2013

                            Lead Product(s) : Interleukin 2

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Recipient : Assistance Publique – Hôpitaux de Paris

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth